ALK and non-small cell lung carcinoma: Tamura et al[11]did a similar study comparing crizotinib, ceritinib, and alectinib in patients with ALK-positive NSCLC, trying to ascertain their effectiveness and long-term impact (3 years); the study showed these drugs’ ORRs.